Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,963.00
Ask: 1,965.00
Change: -36.00 (-1.81%)
Spread: 2.00 (0.102%)
Open: 2,004.00
High: 2,004.00
Low: 1,958.00
Prev. Close: 1,994.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sector movers: M&A gives pharma stocks a big boost

Tue, 22nd Apr 2014 15:28

Pharmaceuticals and biotechnology stocks were rising by an average of six per cent in London on Tuesday, helped by a wave of high-profile M&A deals across the global healthcare sector.Leading the charge in the UK was AstraZeneca on reports that it could be at the centre of the largest deal in pharmaceutical history.Shares were up 7% in afternoon trade after The Sunday Times said that Pfizer could make a takeover approach valuing the group at £60bn. This is a 25% premium to the recent share price and would represent the largest foreign takeover of a UK business on record.While Astra is reported to have rejected an initial offer, analysts at Citigroup said Pfizer is likely to "push aggressively ahead with a second approach".Meanwhile, GlaxoSmithKline (GSK) jumped after announcing a massive three-part deal with Swiss pharmaceuticals peer Novartis, which will see shareholders receive a £4bn capital return.Under the proposed transaction GSK and Novartis are to create a new consumer healthcare business, GSK will acquire Novartis's vaccines business for $5.25bn, and Novartis will buy GSK's oncology portfolio for $16bn.Meanwhile over in the States, Botox maker Allergan is subject to a $47bn takeover offer from Valeant Pharmaceuticals, and Eli Lilly announced that it would buy Novartis's animal health division for $5.4bn in cash.The increased M&A activity gave stocks across the sector a boost today, including Hikma, BTG and NMC Health.Shire was also making strong gains after Jefferies raised its target price for the group, saying that the recent share-price weakness has presented an "attractive buying opportunity". The broker lifted its target for the shares from 3,400p to 3,550p and kept a 'buy' rating.Jefferies actually trimmed its estimates for Shire slightly due to "sluggish" first-quarter ADHD prescriptions trends in the States, but said it still believes earnings will increase at a "robust" compound annual growth rate of 13% over 2013-2018. Top performing sectors so far todayPharmaceuticals & Biotechnology 12,439.17 +5.99%Industrial Metals & Mining 1,196.37 +4.13%Industrial Transportation 3,110.46 +2.36%Electronic & Electrical Equipment 4,269.48 +1.99%Food & Drug Retailers 3,840.40 +1.86%Bottom performing sectors so far todayBC
More News
12 Jan 2023 17:55

Arecor transfers AT307 drug to Hikma for development, regains AT282

(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.

Read more
3 Jan 2023 17:31

FTSE 100 ends first trading day of 2023 on upbeat note

FTSE 100 up 1.4%, FTSE 250 adds 1.5%

*

Read more
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.